StockNews.com upgraded shares of InfuSystem (NYSEAMERICAN:INFU - Free Report) from a buy rating to a strong-buy rating in a report released on Wednesday.
InfuSystem Price Performance
Shares of NYSEAMERICAN:INFU traded down $0.05 during trading on Wednesday, hitting $7.87. 21,780 shares of the stock were exchanged, compared to its average volume of 45,023. InfuSystem has a 1-year low of $7.75 and a 1-year high of $11.44. The firm has a market capitalization of $167.32 million, a PE ratio of 262.42 and a beta of 1.24. The company has a current ratio of 1.95, a quick ratio of 1.54 and a debt-to-equity ratio of 0.56.
Institutional Trading of InfuSystem
Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in InfuSystem by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 1,065,298 shares of the medical instruments supplier's stock worth $11,228,000 after purchasing an additional 23,976 shares in the last quarter. BlackRock Inc. boosted its stake in InfuSystem by 597.8% in the second quarter. BlackRock Inc. now owns 1,029,364 shares of the medical instruments supplier's stock worth $9,913,000 after purchasing an additional 881,856 shares in the last quarter. Punch & Associates Investment Management Inc. boosted its stake in InfuSystem by 3.2% in the third quarter. Punch & Associates Investment Management Inc. now owns 939,918 shares of the medical instruments supplier's stock worth $9,061,000 after purchasing an additional 28,807 shares in the last quarter. Meros Investment Management LP boosted its stake in InfuSystem by 0.4% in the fourth quarter. Meros Investment Management LP now owns 884,090 shares of the medical instruments supplier's stock worth $9,318,000 after purchasing an additional 3,709 shares in the last quarter. Finally, Wasatch Advisors Inc. boosted its stake in InfuSystem by 18.6% in the first quarter. Wasatch Advisors Inc. now owns 859,679 shares of the medical instruments supplier's stock worth $8,425,000 after purchasing an additional 135,076 shares in the last quarter. Institutional investors and hedge funds own 71.13% of the company's stock.
About InfuSystem
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Stories
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
